Viewing nowCabergactin 0.25mg (Cabergoline)
Cabergoline 0.25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 201500627 · Approved 2015.02.05 · Insurance code 657306580
Treatment of hyperprolactinemia; prevention and suppression of lactation
This medication is used to prevent and inhibit milk secretion when a mother does not wish to breastfeed due to medical reasons or after childbirth. Additionally, it helps in controlling milk secretion after stillbirth or miscarriage. This drug is also utilized to treat various symptoms related to hyperprolactinemia, such as amenorrhea, oligomenorrhea, anovulation, and galactorrhea. It can be effectively used in cases of prolactin-secreting pituitary adenoma or idiopathic hyperprolactinemia. Thus, this drug helps in regulating milk secretion post-delivery and alleviates symptoms due to hyperprolactinemia.
This medicine is for oral administration. Dopamine agonists such as this medicine are better tolerated when taken with food; therefore, take this medicine immediately after a meal for all indications. 1. Prevention and suppression of lactation 1) Suppression of lactation: Take 1mg of cabergoline as a single dose on the first day after delivery. 2) Suppression of established lactation: Take 0.25mg of cabergoline every 12 hours for 2 days (total 1mg). 2. Treatment of hyperprolactinemia: The recommended initial dose is 0.5mg of cabergoline once or twice weekly (e.g., 1/2 tablet on Monday and Thursday). Gradually increase the dose by 0.5mg of cabergoline per week, preferably at monthly intervals, until the optimal treatment response is achieved. The usual therapeutic dose is 1mg of cabergoline per week, with a range of 0.5mg ~ 2mg per week. The maximum dose should not exceed 4.5mg of cabergoline per week or 3mg daily. Adjust the dosing frequency to once weekly or twice or more weekly according to the patient's compliance. Tolerability of doses of 1mg or more of cabergoline taken once weekly has been evaluated in only a small number of patients; therefore, if taking 1mg or more of cabergoline per week, divided dosing is recommended. During dose escalation, evaluate the patient to determine the minimum dose that produces a treatment response. Monitor serum prolactin levels monthly. Once an effective therapeutic dose is reached, serum prolactin concentrations usually return to normal within 2~4 weeks. Symptoms of hyperprolactinemia may recur after this medicine is discontinued. In some patients, prolactin levels have been observed to remain low for several months. In follow-up of a group of women who discontinued this medicine, 23 of 29 continued to have ovulatory cycles for more than 6 months after discontinuation.
This medication should not be used in certain patients. For example, individuals with hypersensitivity to this medication or with a history of fibrosis diseases such as pulmonary fibrosis, pericardial fibrosis, or retroperitoneal fibrosis should not take this drug. Patients with severely impaired liver function or those with preeclampsia should also refrain from using this medication. Additionally, individuals currently taking antipsychotic medications, those with a history of postpartum psychosis, or patients diagnosed with valvular heart disease should exercise caution when using this drug for extended periods. Patients with hepatic or renal impairment, severe cardiovascular conditions, Raynaud's syndrome, peptic ulcers, gastrointestinal bleeding, and a history of severe mental disorders should use this medication cautiously. Patients taking antihypertensives may experience hypotensive symptoms, so precautions are advised. Pregnant women or women of childbearing potential should also be careful when taking this drug, and it should not be administered to patients with genetic lactose intolerance issues. Furthermore, patients with severe pituitary tumors causing visual impairment should be administered this drug with caution. This drug can cause side effects depending on the dosage. It is advisable to start at a low dose and gradually increase the dosage to minimize side effects. Common symptoms that may occur while taking this drug include dizziness, headache, abdominal pain, dyspepsia, breast pain, fatigue, and low blood pressure. Other symptoms such as vasospasm in fingers or leg cramps, skin rash, hair loss, depression, sleep disorders, and behavioral changes such as pathological gambling, increased libido, and compulsive buying can also arise. Serious side effects, including valvular heart disease or pulmonary fibrosis, may occur rarely, requiring caution. When taking this medication long-term, regular monitoring of liver and heart function is essential. Particularly, echocardiograms should be used to check for valvular heart disease, and if symptoms arise, the medication should be discontinued immediately. This drug can also cause orthostatic hypotension, leading to dizziness when standing up, so precautions should be taken. This medication can induce narcolepsy or sudden sleep attacks, so care should be taken when driving or operating machinery while taking it. Impulse control disorders may develop, leading to pathological gambling, increased sexual desire, compulsive buying, etc., requiring immediate consultation with a healthcare professional. This drug should not be taken during pregnancy, and it is safe to plan for pregnancy only after at least one month has passed since discontinuation. It is recommended that breastfeeding women discontinue breastfeeding since this drug inhibits milk secretion. Because this drug acts on dopamine receptors, it should not be taken with dopamine antagonists or certain antibiotics. It is also important to discuss potential interactions with other drugs with healthcare professionals.
Postural hypotension, vasospasm of the fingers, syncope, leg cramps, muscle weakness, hair loss, pruritus, rash, allergic skin reactions, decreased hemoglobin levels, depression, sleep disorders, aggression, hypersexuality, pathological gambling, increased libido, dizziness, lightheadedness, headache, sensory disturbances, somnolence, facial flushing, abdominal pain, dyspepsia, gastritis, nausea, constipation, vomiting, breast pain, asthenia, fatigue, somnolence, valvular heart disease, pericarditis, pericardial effusion, palpitations, epistaxis, symptoms of hypotension, pleural effusion, pulmonary fibrosis, upper abdominal pain, asymptomatic hypotension, lethargy, transient blindness, hypersensitivity, delusions, valvular disease, dyspnea, respiratory diseases, respiratory failure, liver dysfunction, edema, elevated serum creatine phosphokinase levels, nausea, discomfort in the stomach area, confusion, psychosis, hallucinations
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a light-protected container. Additionally, it is best stored in a cool place below room temperature (25 degrees Celsius).
White round tablet
24 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCabergoline 0.25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Cabergoline 0.5mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Cabergoline 1mg
Tablet · Prescription medication
Dong-gu Bio Pharmaceutical Co., Ltd.

Cabergoline 0.5mg
Tablet · Prescription medication
Darim Biotech Co., Ltd.

Cabergoline 1mg
Tablet · Prescription medication
Darim Biotech Co., Ltd.

Cabergoline 0.25mg
Tablet · Prescription medication
Darim Biotech Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.